The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis

Basit Öğe Kaydı
dc.contributor.authorTaskiran, Esra
dc.contributor.authorTerzi, Murat
dc.contributor.authorHelvaci, Elif Merve
dc.contributor.authorEser, Meltem Zeycan
dc.contributor.authorAvci, Bahattin
dc.contributor.authorFaruk, Turan Omer
dc.contributor.authorYetkin, Mehmet Fatih
dc.date.accessioned2025-01-27T20:20:19Z
dc.date.available2025-01-27T20:20:19Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground/aim: Multiple sclerosis (MS) is an inflammatory demyelinating central nervous system (CNS) disease. Among the paraclinical tests, brain and spinal Magnetic Resonance Imaging (MRI) is primarily involved in the diagnosis process, and cerebrospinal fluid (CSF) analysis is fundamental in diagnosing MS and the differential diagnosis. A positive relationship was demonstrated between oligoclonal band (OCB) positivity, CSF band number and immunoglobulin G(IgG) index. The study aimed to evaluate whether the number of OCB can predict disease activity and determine a correlation with the IgG index. Methods: Our study included 401 MS patients who had relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), clinic isolated syndrome (CIS), radiologic isolated syndrome (RIS), Neuromyelitis optica spectrum disorder (NMOSD) and Acute disseminated encephalomyelitis (ADEM) with OCB number groups of 2-4, 4-8, 8-12, and 12 and above. Results: No significant correlation was observed between IgG index, pre-and post-treatment EDSS (Expanded Disability Status Scale Scores) and disease-modifying therapies (DMT). Drug response was better in the patient group with band number between 2 and 8 and post-treatment EDSS scores were lower (1.62 +/- 0.44). Conclusion: The study results suggested that band number may be as valuable as the IgG index and a predictive biomarker for disease activity.
dc.identifier.doi10.1016/j.msard.2023.105391
dc.identifier.issn2211-0348
dc.identifier.issn2211-0356
dc.identifier.pmid38335838
dc.identifier.scopus2-s2.0-85184758603
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.msard.2023.105391
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21667
dc.identifier.volume83
dc.identifier.wosWOS:001185823200001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.ispartofMultiple Sclerosis and Related Disorders
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectMultiple sclerosis
dc.subjectOligoclonal band number
dc.subjectImmunoglobulin IgG index
dc.subjectDisease activity
dc.subjectTreatment
dc.subjectBiomarker
dc.titleThe role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu